NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

Core Insights - Nanobiotix has entered into a royalty-based financing agreement with HealthCare Royalty, providing up to $71 million in non-dilutive capital to support its growth and development of nanotherapeutic platforms [1][2][5]. Financing Agreement Details - The agreement includes an upfront payment of $50 million, with an additional $21 million expected one year post-closing, contingent on certain conditions [7]. - The financing extends Nanobiotix's cash runway into early 2028, allowing the company to advance through critical milestones towards self-sustainability [5][6]. - HealthCare Royalty will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3), with repayment obligations structured around a defined portion of royalties on the first $1 billion of net sales [7][6]. Product Overview - JNJ-1900 (NBTXR3) is a novel oncology product utilizing functionalized hafnium oxide nanoparticles, administered via intratumoral injection and activated by radiotherapy [6][8]. - The product has shown promise in clinical trials, particularly in soft tissue sarcomas, and is being evaluated for multiple solid tumor indications [9][8]. Strategic Partnerships - Nanobiotix has engaged in a collaboration strategy to expand the development of JNJ-1900 (NBTXR3), including a partnership with The University of Texas MD Anderson Cancer Center for various clinical studies [10]. - In 2023, a global co-development and commercialization license agreement was established with Janssen Pharmaceutica NV, a Johnson & Johnson company [10]. Company Background - Nanobiotix is a late-stage clinical biotechnology company focused on innovative, physics-based therapeutic approaches to improve cancer treatment outcomes [11][12]. - The company is headquartered in Paris, France, and is listed on Euronext Paris and the Nasdaq Global Select Market [12].